# A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

> **NCT06754462** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Immunovant Sciences GmbH** · enrollment: 120 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** IMVT-1402
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06754462
- **Lead sponsor:** Immunovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06754462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06754462, "A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06754462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*